Wire · opportunities
Compass Pathways Just Answered the Durability Question. Now Comes the Harder Problem.
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
Compass Pathways' Phase 3 trial data shows durable efficacy for psilocybin therapy in treatment-resistant depression, but major challenges remain in scaling patient access due to therapist shortages, certification gaps, reimbursement infrastructure, and regulatory scheduling delays.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.
◆ ◆ The Wire takeaway
The breakthrough in psilocybin's lasting clinical effect turns your attention to the looming bottleneck of therapist supply and payment systems. You need to start building or partnering on therapy delivery and reimbursement solutions now to avoid missing the commercial window.
◆ Coverage
1 source · 15 Sep 2026
◆ Related on Wire
◆ Topics